No clinical efficacy or safety issues raised
Citius committed to working toward approval
CRANFORD, N.J., July 29, 2023 /PRNewswire/ Citius Pharmaceuticals, Inc. today announced that the U.S..
Citius Pharmaceuticals (CTXR) Reports Positive Results from the Phase 2b Study of Halo-Lido streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone
Dose for Phase 3 trial selected; Citius to schedule end of Phase 2 meeting with the. | June 20, 2023
/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.